Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery

Journal of Clinical Oncology 2026 Open access

Read full text
Authors: Andrew B. Lassman, Mei-Yin C. Polley, FABIO MASSAITI IWAMOTO, Vinai Gondi, Erik P. Sulman, Jedd D. Wolchok, Minesh P. Mehta
DOI: 10.1200/jco-25-02821
Cited by: 1
References: 8

Abstract

We appreciate the interest in our work and the comments from Wang et al 1 who raise interesting points about the blood-brain barrier (BBB) and dosing of immune checkpoint inhibitors (ICIs) as potential reasons for treatment failure in the National Cancer Institute

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Vagus Nerve Stimulation Research Barrier Structure and Function Studies

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
13
Pages
1267–1268
Publication date
16 January 2026
Language
EN